Advertisement

On the Horizon: The Specialty Pharmacy Pipeline

Specialty medications represent about 1.5% to 2.5% of prescriptions but comprise approximately 50% of total prescription costs. The average cost of a specialty drug...

How to Manage Generics When They Become Too Costly

There is insufficient competition in the generic drug marketplace, and market consolidation has led to price increases. Because of a lack of appropriate alternatives...

Real-Time Benefit Checks May Improve Medication Adherence, Reduce Patient Costs

Providers often have a limited knowledge of a specific patient’s insurance coverage when prescribing medications, and a real-time benefit check program may be a...

Tips for Addressing the Medical Pharmacy Benefit Spend

A total of 49 specialty drugs were approved in 2018: 25 managed through the medical benefit, 19 through the pharmacy benefit, and...

Switching Biologics Is Costlier Among Patients With Psoriasis

A recent study assessed the costs associated with switching biologic agents for patients with psoriasis. The authors found that compared with persistent users, patients who...

Limiting Pharmaceutical Coupon Use Is More Cost-Effective

Coupons are commonly marketed to patients and prescribers to insulate patients from higher costs associated with brand-name drugs. However, these coupons can...

Session Puts a Spotlight on Health Care Disruptors and Innovators

Despite its rising level of health care spending, the United States lags behind other countries in many outcomes and quality measures. Much of the...

AMCP Headline Session: Trends and Development in Pharmaceuticals

During a presentation at the AMCP Annual Meeting, Douglas M. Long, BS, MBA, vice president of industry relations at Iqvia in Ponte Vedra...

How to Address the Drug Coupon Challenge

The number of drugs with copay cards has soared in the past 10 years, from 75 drugs in 2009 to 700 drugs...

Best Practices for Navigating Preapproval Information Exchange

Preapproval information exchange is the communication between biopharmaceutical companies and population health decision-makers on topics such as phase III clinical trial data, pharmacoeconomic data,...
Advertisement